^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

mono TRuC-T CD70 cell therapy

i
Other names: mono TRuC-T CD70 cell therapy
Associations
Trials
Company:
Adaptimmune
Drug class:
TCR modulator, CD70 inhibitor
Related drugs:
Associations
Trials
3years
A Membrane-Tethered IL-15/IL-15 Receptor Fusion Protein Enhances the Persistence and Efficacy of CD70-Targeted TRuC-T Cells (SITC 2021)
In vivo, the anti-tumor activity of CD70-targeted TRuC-T cells was significantly improved by IL-15fu in multiple tumor models and was associated with enhanced intratumoral T-cell accumulation and a preferential expansion of CD8+ T cells. Conclusions The addition of the IL-15fu improved the phenotype, persistence, and anti-tumor activity of CD70-targeted TRuC-T cells, potentially increasing the likelihood of clinical benefit in patients with CD70 overexpressing solid and liquid cancers.
Clinical • IO biomarker
|
CD8 (cluster of differentiation 8) • CD70 (CD70 Molecule)
|
CD70 expression • CD70 overexpression
|
mono TRuC-T CD70 cell therapy